ArticleInternational journal of hematology2011
Utility of laboratory tests in B-CLL patients in different clinical stages.
Article in International journal of hematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study objective was to analyse the utility of laboratory tests performed in 30 patients with B-cell chronic lymphocytic leukaemia (B-CLL) at different clinical stages. Laboratory tests included automated and microscopic assessment of peripheral blood and bone marrow counts as well as evaluation of leukaemic cells. Apart from the diagnostic and prognostic value of laboratory abnormalities such as clonal lymphocytosis with CD5+CD19+CD23+ phenotype, reduced erythrocyte parameters, thrombocytopenia or bone marrow infiltration by the neoplastic clone as well as low percentage of Gumprecht's shadows, low apoptotic activity of peripheral blood lymphocytes, and increased percentage of CD38- and ZAP-70 ± cells markedly correlate with the stage of disease progression. These results seem to confirm the diagnostic and prognostic significance of these parameters determined in routine laboratory tests in B-CLL patients.
Indexed as
Identifiers
21626106What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.